Ambry Genetics, a prominent provider of clinical genomic testing, which is now a fully owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), has declared the successful completion of its one millionth DNA/RNA test. This milestone highlights their dedication to ensuring diagnostic precision. Over ten years ago, Ambry Genetics was the first in the industry to introduce paired DNA/RNA testing for hereditary cancer. Presently, they remain as one of the few laboratories that provide RNA testing information for both hereditary cancer and other conditions.